Swiss National Bank
RPTX

Swiss National Bank’s Repare Therapeutics RPTX Stock Holding History

Swiss National Bank’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-40,700
Closed -$492K – 2598
2023
Q3 		$492K Hold
40,700
– – ﹤0.01% 2512
2023
Q2 		$431K Hold
40,700
– – ﹤0.01% 2562
2023
Q1 		$400K Sell
40,700
-4,800
-11% -$55.1K ﹤0.01% 2571
2022
Q4 		$669K Buy
45,500
+1,200
+3% +$17.9K ﹤0.01% 2500
2022
Q3 		$537K Hold
44,300
– – ﹤0.01% 2540
2022
Q2 		$620K Buy
44,300
+4,800
+12% +$56.5K ﹤0.01% 2558
2022
Q1 		$562K Buy
39,500
+2,600
+7% +$38.6K ﹤0.01% 2577
2021
Q4 		$778K Buy
36,900
+16,100
+77% +$379K ﹤0.01% 2558
2021
Q3 		$546K Hold
20,800
– – ﹤0.01% 2574
2021
Q2 		$649K Hold
20,800
– – ﹤0.01% 2593
2021
Q1 		$638K Hold
20,800
– – ﹤0.01% 2434
2020
Q4 		$713K Buy
+20,800
New +$621K ﹤0.01% 2408

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Swiss National Bank's RPTX Position: Q4 2023 in Review

Swiss National Bank sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 40,700 shares — an estimated $492K sold.

Swiss National Bank first reported a position in RPTX in Q4 2020 and held it in 12 quarters. The position peaked at $778K in Q4 2021. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • Swiss National Bank reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Swiss National Bank sold 40,700 Repare Therapeutics shares in Q4 2023, an estimated $492K.
  • Swiss National Bank first reported a position in Repare Therapeutics in Q4 2020 and held it in 12 quarters.
  • Swiss National Bank's Repare Therapeutics position peaked at $778K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.